Sophia Genetics
Follow Sophia Genetics on Notably News to receive short updates to your email — rarely!
| March 2025 | The company announced reaching a milestone of 2 million genomic profiles analysed using its Sophia DDM platform. |
| 2024 | Entered a collaboration with NVIDIA and Microsoft to launch a whole-genome sequencing application. |
| October 2023 | Entered a partnership with AstraZeneca and Memorial Sloan Kettering Cancer Center to offer blood and tumor sequencing tests to more hospitals and patients worldwide via Sophia's data-driven medicine platform. |
| March 2023 | Paired technology with Qiagen for somatic variant detection. |
| 2022 | Committed to a collaboration with Memorial Sloan Kettering Cancer Center to advance predictive tumor analysis and clinical decision support. |
| 2022 | The firm began developing a new method for detecting extrachromosomal DNA through a collaboration with startup firm Boundless Bio. |
| 2021 | Collaborated with GE HealthCare to build an analytics platform for matching patients' treatment regimens based on genomic signature, cancer type, and health record. |
| 2021 | Partnered with MGI (a BGI Group subsidiary) to enable users to access the SOPHiA DDM Platform for data analysis and interpretation. |
| July 2021 | Sophia Genetics went public with an Initial Public Offering (IPO) backed by J.P. Morgan, Morgan Stanley, and Credit Suisse. |
| March 2021 | Announced a long-term collaboration agreement with Hitachi. |
| August 2020 | The company released a data analysis solution specifically designed to predict the disease evolution of the SARS-CoV-2 virus. |
| 2019 | Formed partnerships with Integrated DNA Technologies and Paragon Genomics to provide COVID-19 test kits. |
| 2018 | Sophia Genetics established its first research and development center in France and acquired Interactive Biosoftware, a French molecular biology and genetic analytics software development company. In the same year, the company opened its U.S. headquarters in Boston, Massachusetts. |
| 2016 | Entered into a comarketing agreement with Illumina to promote adoption of next-generation DNA sequencing. |
| 2014 | The company introduced the Sophia DDM Platform (Data-Driven Medicine), an analytical software platform for interpreting circulating tumor DNA and cells in various biological samples, spanning multiple medical fields including oncology and rare disease research. |
| 2011 | Sophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz at École Polytechnique Fédérale de Lausanne (EPFL) as a start-up focused on research tools for hospitals and healthcare labs. |
This contents of the box above is based on material from the Wikipedia article Sophia Genetics, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.